The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Lengo Therapeutics
Phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations.
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Blueprint Medicines; Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Astellas Pharma
 
Lova Sun
No Relationships to Disclose
 
Danny Nguyen
Stock and Other Ownership Interests - Intuitive Surgical (I); Teladoc (I)
Other Relationship - Takeda
 
Paul Pearson
Employment - Lengo Therapeutics
Consulting or Advisory Role - Blueprint Medicines
 
Jennifer Shim-Lopez
No Relationships to Disclose
 
Diana Felice Hausman
Employment - Lengo Therapeutics
Consulting or Advisory Role - Blueprint Medicines
 
Xiuning Le
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; EMD Serono; Lilly; Spectrum Pharmaceuticals
Research Funding - Boehringer Ingelheim (Inst); Lilly (Inst)